# Document

![rw-book-cover](https://readwise-assets.s3.amazonaws.com/static/images/article1.be68295a7e40.png)

## Metadata
- Author: [[readwise.io]]
- Full Title: Document
- Category: #articles
- URL: https://readwise.io/reader/document_raw_content/98875096

## Highlights
- Phase 2B ­clinical trial—typically the second-to-last stage before a drug gets the FDA’s nod ([View Highlight](https://read.readwise.io/read/01hcfj5sqwyg4cv5bxhdf17mpd))
    - Tags: [[important]] 
- The Compass founders say they first encountered psilocybin after Malievskaia’s son developed acute depression and obsessive-compulsive disorder in 2012 during his first semester of college. Months of $960-an-hour psychiatric appointments didn’t seem to help, nor did pills or an inpatient OCD program. “He was getting worse and worse,” she says. “They were just sitting there shaking their heads.” One sleepless night in 2013, she read a Heffter- funded study that concluded psilocybin use had helped ameliorate symptoms among a small group of OCD patients at the University of Arizona. Goldsmith and Malievskaia contacted Nichols, who invited them to the next Heffter board meeting. The couple were so impressed with the discussion that they wrote Nichols a check for $100,000. By 2014 therapist-supervised use of psychedelics and ket- amine had helped Malievskaia’s son recover, and the couple thought about how they could make similar treatment available to a much wider audience. Why not start asking regulators what it might take? ([View Highlight](https://read.readwise.io/read/01hcfhxmdvcvq8byfbxdvsadxh))
    - Note: explanation of use in college student
- Today’s go-to treat- ments, psycho­therapy and selective serotonin reuptake inhibitors, work for only about 70% of patients, leaving as many as 90 million still strug- gling around the globe, according to the World Health Organization. ([View Highlight](https://read.readwise.io/read/01hcfhrw6vrg8fxz58afgvhqdk))
- “The rise of the for-profit psychedelic pharma efforts are a sign of our success over the last 33 years in changing the political dynamics at the FDA, changing the public attitudes toward this,” ([View Highlight](https://read.readwise.io/read/01hcfhtmzr7jewjwj7gyfs810c))
